Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 14, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13045-021-01070-w
Keywords
Neddylation; UBE2M; UBE2F; Therapeutic targets; Anticancer treatment
Categories
Funding
- National Key Research Program of Proteins [2016YFA0501800, 2018YFE0195100]
- Key Research Program of Henan Province [161100310100]
- National Natural Science Foundation of China [81602961, 81430085, 82020108030, 81773562, U1804191]
- Science and Technology Innovation Talents of Henan Provincial Education Department [19IRTSTHN001]
- Science and Technology Project of Henan Province [202102310145]
Ask authors/readers for more resources
UBE2M and UBE2F are two enzymes in the NEDD8-conjugating pathway, playing important roles in posttranslational modification and potential cancer treatment targets.
Ubiquitin-conjugating enzyme E2 M (UBE2M) and ubiquitin-conjugating enzyme E2 F (UBE2F) are the two NEDD8-conjugating enzymes of the neddylation pathway that take part in posttranslational modification and change the activity of target proteins. The activity of E2 enzymes requires both a 26-residue N-terminal docking peptide and a conserved E2 catalytic core domain, which is the basis for the transfer of neural precursor cell-expressed developmentally downregulated 8 (NEDD8). By recruiting E3 ligases and targeting cullin and non-cullin substrates, UBE2M and UBE2F play diverse biological roles. Currently, there are several inhibitors that target the UBE2M-defective in cullin neddylation protein 1 (DCN1) interaction to treat cancer. As described above, this review provides insights into the mechanism of UBE2M and UBE2F and emphasizes these two E2 enzymes as appealing therapeutic targets for the treatment of cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
